Medscape Hematology-Oncology is pleased to present the latest update to the NCCN Clinical Practice Guidelines in Oncology™ Prostate Cancer, released in December 2009. The updated NCCN Guideline, ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...
SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing, commends the updated Prostate Cancer Guidelines from the National ...
Data from a nationwide German registry with data from nearly 3,000 long-term survivors of radical prostatectomy sheds light on how frailty impacts the lives they lead. Treat or observe? Dr. Joseph ...
In a groundbreaking recommendation, the National Comprehensive Cancer Network (NCCN) has broadened the scope of prostate cancers that qualify for active surveillance in the United States to include ...
The Viz Oncology Suite is a clinical decision support system that integrates seamlessly with the electronic health record to ...
The National Comprehensive Cancer Network, a coalition of 33 leading U.S. cancer centers, has rolled out a digital navigator for its clinical practice guidelines. The new tool delivers frequently ...
The new interactive guideline tool represents a major format change for gold-standard NCCN Guidelines. "This is truly the future of cancer treatment guidance," said Crystal S. Denlinger, MD, Chief ...
Patients who receive guideline-concordant treatment for nonmetastatic prostate cancer are more likely to die from other causes. Men with nonmetastatic prostate cancer (PCa) who receive treatment ...
Men diagnosed with nonmetastatic low- and intermediate-risk prostate cancer up to 6 times more likely to die of other causes. HealthDay News — Men with nonmetastatic prostate cancer receiving ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the launch of its Decipher Prostate Metastatic Genomic ...
Risk of death and cause of death 30 years after diagnosis as a proportion of 100 men. Grey figures indicate the proportion of men alive after 30 years, blue figures the proportion of men who died of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback